4.5 Article

Multiscale Modeling in the Clinic: Drug Design and Development

期刊

ANNALS OF BIOMEDICAL ENGINEERING
卷 44, 期 9, 页码 2591-2610

出版社

SPRINGER
DOI: 10.1007/s10439-016-1563-0

关键词

Pharmacology; Mathematical; Multiscale modeling; Simulation; Drug delivery

资金

  1. NIH [R01CA138264, U01HL126273, U01EB016027, R01EB006818, R01-GM-115839, P30-DK-42086, R01GM077138, R15EB015105]
  2. EPA [R835001]
  3. Laboratory Directed Research Program at Pacific Northwest National Laboratory
  4. U.S. Department of Energy [DE-AC06-76RLO]
  5. EPA [R835001, 150263] Funding Source: Federal RePORTER

向作者/读者索取更多资源

A wide range of length and time scales are relevant to pharmacology, especially in drug development, drug design and drug delivery. Therefore, multiscale computational modeling and simulation methods and paradigms that advance the linkage of phenomena occurring at these multiple scales have become increasingly important. Multiscale approaches present in silico opportunities to advance laboratory research to bedside clinical applications in pharmaceuticals research. This is achievable through the capability of modeling to reveal phenomena occurring across multiple spatial and temporal scales, which are not otherwise readily accessible to experimentation. The resultant models, when validated, are capable of making testable predictions to guide drug design and delivery. In this review we describe the goals, methods, and opportunities of multiscale modeling in drug design and development. We demonstrate the impact of multiple scales of modeling in this field. We indicate the common mathematical and computational techniques employed for multiscale modeling approaches used in pharmacometric and systems pharmacology models in drug development and present several examples illustrating the current state-of-the-art models for (1) excitable systems and applications in cardiac disease; (2) stem cell driven complex biosystems; (3) nanoparticle delivery, with applications to angiogenesis and cancer therapy; (4) host-pathogen interactions and their use in metabolic disorders, inflammation and sepsis; and (5) computer-aided design of nanomedical systems. We conclude with a focus on barriers to successful clinical translation of drug development, drug design and drug delivery multiscale models.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据